PCSK9 Inhibitors: A Guide for Managed Care

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

On this episode of Managed Care Cast, we're talking with the chief science officer of the Center for Innovation & Value Research about key insights from its Rare Disease project.

The prior authorization process for patients with cancer demonstrates fewer days until submission and lower denial rates for Asian patients relative to White patients.

September is National Recovery Month, and we are bringing you another limited-edition month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In our final episode, we speak with Lyndra Bills, MD, and Shari Hutchison, MS.

CMS released a preliminary list of 101 generic drugs for its Medicare $2 Drug List Model, which aims to cap out-of-pocket costs at $2 per month for select medications.

Patients with refractory metastatic colorectal cancer could use trifluridine/tipiracil (TAS-102) plus bevacizumab as a cost effective third line treatment in China but the same was not found in the United States and United Kingdom.